DIR Return Create A Forum - Home
       ---------------------------------------------------------
       MS Speaks
  HTML https://msspeaks.createaforum.com
       ---------------------------------------------------------
       *****************************************************
   DIR Return to: TREATMENTS
       *****************************************************
       #Post#: 5234--------------------------------------------------
       UTIs, urosepsis, and MS DMTs: A disproportionality analysis of
       the FDA FAERS
   DIR By: agate
       Date: July 12, 2026, 10:39 am
       ---------------------------------------------------------
       Entire article from Multiple Sclerosis Journal (June 29, 2026),
       report on a Harvard study--"Urinary tract infections, urosepsis,
       and multiple sclerosis disease-modifying therapies: a
       disproportionality analysis of the FDA Adverse Event Reporting
       System":
  HTML https://www.msard-journal.com/article/S2211-0348(26)00387-1/fulltext
       Excerpts:
       --- Quote ---
       > Immunomodulatory disease modifying therapies (DMTs) have
       transformed the management of multiple sclerosis (MS), however,
       their infectious risks have become increasingly apparent as use
       has expanded. Population-level studies indicate that infections
       are a leading contributor to morbidity and mortality in advanced
       MS, with urinary tract infections (UTIs) frequently implicated.
       (Kingwell et al., 2020
  HTML https://www.msard-journal.com/article/S2211-0348(26)00387-1/fulltext#];<br
       />Harding et al., 2020
  HTML https://www.msard-journal.com/article/S2211-0348(26)00387-1/fulltext#)<br
       />These infections likely reflect the combined effects of
       neurogenic lower urinary tract dysfunction (NLUTD) and DMT
       immunomodulation. This study evaluated which MS DMTs are
       associated with disproportionately high UTI and urosepsis
       reporting using the FDA Adverse Event Reporting System (FAERS).
       >
       > And this excerpt:
       >
       > Discussion:
       >
       > ]This real-world pharmacovigilance study using the FAERS
       identified disproportionally high reporting of UTI and urosepsis
       across several MS DMTs. Ocrelizumab demonstrated the largest UTI
       RORs, while natalizumab, alemtuzumab, and interferon beta-1a
       were most consistently linked with urosepsis across all sex and
       age subgroups. In line with epidemiologic data, females
       experienced more UTIs and resulting urosepsis. ... Overall,
       these infections carried substantial morbidity and mortality,
       with nearly 7000 hospitalizations and over 500 deaths.
       --- End Quote ---
       If readers cannot see the entire article, I would appreciate it
       if I could be notified. The findings presented here strike me as
       noteworthy even though the study did not include older persons
       with MS. UTIs are sometimes easily treated but can be extremely
       uncomfortable--and can all too often involve the kidneys and
       lead to major infections involving hospitalization and even
       death.
       *****************************************************
       Page 1 of 1